Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium.
Abstract The clear cell subtype of kidney cancer encompasses most renal cell carcinoma cases and is associated with the loss of von Hippel-Lindau gene function or expression. Subsequent loss or mutation of the other allele influences cellular stress responses involving nutrient and hypoxia sensing. Autophagy is an important regulatory process promoting the disposal of unnecessary or degraded cellular components, tightly linked to almost all cellular processes. Organelles and proteins that become damaged or that are no longer needed in the cell are sequestered and digested in autophagosomes upon fusing with lysosom...
Source: Cancer Journal - May 1, 2019 Category: Cancer & Oncology Authors: Russell KL, Gorgulho CM, Allen A, Vakaki M, Wang Y, Facciabene A, Lee D, Roy P, Buchser WJ, Appleman LJ, Maranchie J, Storkus WJ, Lotze MT Tags: Cancer J Source Type: research

Introduction by the Guest Editor, Terry J. Fry.
PMID: 31135524 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - May 1, 2019 Category: Cancer & Oncology Authors: Fry TJ Tags: Cancer J Source Type: research

T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.
Abstract Adoptive immunotherapy with engineered T cells is at the forefront of cancer treatment. T cells can be engineered to express T-cell receptors (TCRs) specific for tumor-associated antigens (TAAs) derived from intracellular or cell surface proteins. T cells engineered with TCRs (TCR-T) allow for targeting diverse types of TAAs, including proteins overexpressed in malignant cells, those with lineage-restricted expression, cancer-testis antigens, and neoantigens created from abnormal, malignancy-restricted proteins. Minor histocompatibility antigens can also serve as TAAs for TCR-T to treat relapsed hematolog...
Source: Cancer Journal - May 1, 2019 Category: Cancer & Oncology Authors: Biernacki MA, Brault M, Bleakley M Tags: Cancer J Source Type: research

Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia.
Abstract Chimeric antigen receptor (CAR) T-cell therapy is transforming the landscape for treatment of B-lineage acute lymphoblastic leukemia (B-ALL). Chimeric antigen receptor T-cell therapy makes use of T cells that have been modified to target a cancer-specific cell surface antigen. There is currently 1 Food and Drug Administration-approved CD19-directed CAR T-cell therapy for relapsed/refractory B-ALL with numerous other CAR T-cell products under clinical investigation. This review covers the development of CAR T cells for B-ALL, citing the remarkable efficacy of inducing remissions in a very high-risk populat...
Source: Cancer Journal - May 1, 2019 Category: Cancer & Oncology Authors: Ceppi F, Gardner RA Tags: Cancer J Source Type: research

Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Abstract Refractory and relapsed acute myeloid leukemia (AML) and T-lineage leukemia have poor prognosis and limited therapeutic options. Adoptive cellular immunotherapies are emerging as an effective treatment for patients with chemotherapy refractory hematological malignancies. Indeed, the use of unselected donor lymphocyte infusions has demonstrated successes in treating patients with AML and T-lineage leukemia post-allogeneic transplantation. The development of ex vivo manipulation techniques such as genetic modification or selection and expansion of individual cellular components has permitted the clinical tr...
Source: Cancer Journal - May 1, 2019 Category: Cancer & Oncology Authors: Lulla PD, Mamonkin M, Brenner MK Tags: Cancer J Source Type: research

Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells.
Abstract Multiple myeloma is still an incurable malignancy despite the many new therapies approved over the last decade and therefore represents a significant unmet medical need. To address this need, adoptive cellular therapies using chimeric antigen receptor (CAR) T-cells are being explored in clinical investigations. The number of CAR T-cell trials for multiple myeloma has increased exponentially over the past few years. Although the data are preliminary at this time, the results have garnered much enthusiasm in the field. Immune therapies targeting B-cell maturation antigen have been the most widely developed,...
Source: Cancer Journal - May 1, 2019 Category: Cancer & Oncology Authors: Shah UA, Smith EL Tags: Cancer J Source Type: research

Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.
Abstract Chimeric antigen receptor (CAR) T-cell therapy has been transformative for the treatment of B-cell malignancies, with CD19- and CD22-directed CARs being prime examples. However, immunoediting and ensuing antigen loss remain the major obstacles to curative therapy in up to 25% of patients. For example, to achieve the CD19-negative phenotype, malignant cells can pick from a broad array of mechanisms, including focal loss-of-function mutations, dysregulated trafficking to the cell surface, alternative splicing, and lineage switching. In other cases, where resistance is mediated by insufficient antigen densit...
Source: Cancer Journal - May 1, 2019 Category: Cancer & Oncology Authors: Zheng S, Asnani M, Thomas-Tikhonenko A Tags: Cancer J Source Type: research

Management of T-Cell Engaging Immunotherapy Complications.
This article will discuss T-cell-mediated immunotherapy complications and their suggested management. It is not intended to be comprehensive or applicable to every patient, so practitioners should exercise sound clinical judgment. Rather, this may serve as a starting point for further management discussions in the community. PMID: 31135530 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - May 1, 2019 Category: Cancer & Oncology Authors: Varadarajan I, Lee DW Tags: Cancer J Source Type: research

Treatment According to a Comprehensive Molecular Profiling Can Lead to a Better Outcome in Heavily Pretreated Patients With Metastatic Cancer: Data of a Pooled Analysis.
CONCLUSIONS: We conclude that pretreated cancer patients can benefit from incorporation of molecular profiling, as demonstrated by not only an increase of the PFS ratio but also PFS. Further randomized trials in specific tumor subtypes may help establish specific patient populations who might benefit most from MMP guidance. PMID: 30896526 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Authors: Seeber A, Chahine G, Nasr F, Dean A, Miranova M, Jameson G, Robert N, Gastl G, Zwierzina H Tags: Cancer J Source Type: research

Multiplatform Molecular Profiling: A Precision Medicine Victory Built on Cytotoxic Chemotherapy.
PMID: 30896527 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Authors: Cantor E, Koschmann C Tags: Cancer J Source Type: research

Introduction: Repurposed Drugs: Teaching an Old Dog New Tricks.
PMID: 30896528 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Authors: Sukhatme VP Tags: Cancer J Source Type: research

Identifying Drug Repurposing Opportunities in Oncology.
Abstract The never-ending explosion in the cost of new oncology drugs is reducing in many countries the access to the most recent, effective anticancer therapies and represents a significant obstacle to the design and realization of combinatorial trials. Already approved, anticancer and nonanticancer drugs can be considered for in silico, preclinical, and clinical repurposing approaches and offer the significant advantages of a potentially cheaper, faster, and safer validation. This review discusses recent advances and challenges in the field. PMID: 30896529 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Authors: Orecchioni S, Roma S, Raimondi S, Gandini S, Bertolini F Tags: Cancer J Source Type: research

Repurposing Food and Drug Administration-Approved Drugs to Promote Antitumor Immunity.
Abstract There has been a major resurgence of interest in immune-based approaches to treat cancer, based largely on the success of checkpoint inhibitors (anti-cytotoxic T-lymphocyte-associated antigen 4, anti-programmed cell death 1, and anti-programmed cell death ligand 1 antibodies) in several malignancies. However, not all tumors respond to checkpoint therapy, and there is clearly a need for additional approaches for enhancing tumor immunity. We summarize the critical elements necessary for mounting an efficacious T-cell response to a tumor. We cite drugs approved by the Food and Drug Administration for no-canc...
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Authors: Sukhatme VV, Ramalingam SS, Ahmed R, Sukhatme VP Tags: Cancer J Source Type: research

Perioperative Therapies-Using Repurposed Drugs to Improve Cancer Surgery Outcomes.
DISCUSSION: The perioperative setting is not as well established as the neoadjuvant and adjuvant settings, making identification of relevant research and clinical trials difficult. Despite the potential benefits of such interventions, there is a need for more well-designed clinical trials, additional research, and biomarkers of response. PMID: 30896531 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Authors: Pantziarka P, Bouche G Tags: Cancer J Source Type: research

Repurposing Drugs for Cancer Radiotherapy: Early Successes and Emerging Opportunities.
Abstract It has long been recognized that combining radiotherapy with cytotoxic drugs such as cisplatin can improve efficacy. However, while concurrent chemoradiotherapy improves patient outcomes, it comes at costs of increased toxicity. A tremendous opportunity remains to investigate drug combinations in the clinical setting that might increase the benefits of radiation without additional toxicity. This chapter highlights opportunities to apply repurposing of drugs along with a mechanistic understanding of radiation effects on cancer and normal tissue to discover new therapy-modifying drugs and help rapidly trans...
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Authors: Khan MK, Nasti TH, Buchwald ZS, Weichselbaum RR, Kron SJ Tags: Cancer J Source Type: research

Transcriptome Signature Reversion as a Method to Reposition Drugs Against Cancer for Precision Oncology.
This article reviews methodology of TSR and critically discusses key TSR studies. In addition, potential conceptual and computational improvements of this novel methodology are discussed as well as its current and possible future application in precision oncology trials. PMID: 30896533 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Authors: Koudijs KKM, Terwisscha van Scheltinga AGT, Böhringer S, Schimmel KJM, Guchelaar HJ Tags: Cancer J Source Type: research

Repurposed Drugs for Prostate Cancer.
PMID: 30896534 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Authors: Xu W, Bubley GJ Tags: Cancer J Source Type: research

Repurposed Drugs Trials by Cancer Type: Lung Cancer.
PMID: 30896535 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Authors: Murray JC, Levy B Tags: Cancer J Source Type: research

Repurposed Drugs in Pancreatic Ductal Adenocarcinoma: An Update.
PMID: 30896536 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Authors: Ilmer M, Westphalen CB, Niess H, DʼHaese JG, Angele MK, Werner J, Renz BW Tags: Cancer J Source Type: research

Repurposed Drugs in Treating Glioblastoma Multiforme: Clinical Trials Update.
PMID: 30896537 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Authors: Yadavalli S, Yenugonda VM, Kesari S Tags: Cancer J Source Type: research

Non-Cancer Drug Repurposing Candidates for Renal Cell Carcinoma.
PMID: 30896538 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Authors: Au L, Koudijs KKM, Terwisscha van Scheltinga AGT, Guchelaar HJ Tags: Cancer J Source Type: research

Repurposed Drugs Trials for Ovarian Cancer.
PMID: 30896539 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Authors: DiFeo A Tags: Cancer J Source Type: research

Clinical Trials of Repurposing Medicines in Acute Myeloid Leukemia: Limitations and Possibilities in the Age of Precision Therapy.
PMID: 30896540 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Authors: Andresen V, Gjertsen BT Tags: Cancer J Source Type: research

Erratum.
ERRATUM. Cancer J. 2019 Mar/Apr;25(2):164 Authors: PMID: 30896541 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Cancer J Source Type: research

Introduction by the Guest Editor: At a Crossroad to Cure: From Molecule to Management Strategies in Multiple Myeloma.
PMID: 30694853 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - January 1, 2019 Category: Cancer & Oncology Authors: Munshi NC Tags: Cancer J Source Type: research

Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.
Abstract In the modern era of multiple myeloma therapeutics, proteasome inhibitor (PI) and immunomodulatory drugs (IMiDs) have replaced chemotherapy regimens for newly diagnosed multiple myeloma patients. Treatment combinations that comprise both first- and next-generation PIs, including bortezomib, carfilzomib, and ixazomib and IMiDs, including thalidomide and lenalidomide, have been evaluated in phases II and III clinical trials and have shown significant efficacy with manageable toxicity profiles. Bortezomib or carfilzomib with lenalidomide and dexamethasone (VRD and KRD) are the most promising regimens resulti...
Source: Cancer Journal - January 1, 2019 Category: Cancer & Oncology Authors: Ntanasis-Stathopoulos I, Terpos E, Dimopoulos MA Tags: Cancer J Source Type: research

Contribution of Inhibition of Protein Catabolism in Myeloma.
Abstract Multiple myeloma (MM) is a cancer of plasma cells, characterized by abundant synthesis of monoclonal immunoglobulins and/or free light chains. Although MM remains incurable, median overall survival has considerably improved over the past 2 decades largely due to the introduction of novel agents, including proteasome inhibitors (PIs) and immunomodulatory drugs. Bortezomib, a reversible boronate PI, was the first Food and Drug Administration-approved PI in MM and subsequently mantle cell lymphoma. Carfilzomib and ixazomib, the former an irreversible epoxyketone and the latter an orally bioavailable reversib...
Source: Cancer Journal - January 1, 2019 Category: Cancer & Oncology Authors: Bianchi G, Anderson KC Tags: Cancer J Source Type: research

Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma.
Abstract Over the last 2 decades, thalidomide analogs have induced significant antimyeloma effects via immune-modulation, antiangiogenesis and antiproliferative effects. While the exact molecular mechanism of the targets or the mediators of thalidomide activity were not known, a seminal discovery of cereblon as a thalidomide-binding protein led to explaining the mechanistic basis of antimyeloma activity for this class of agents. Identification of the mechanisms of resistance for immunomodulatory agents (IMiDs), which will have significant clinical implications, remains poorly understood. Newer cereblon modulators ...
Source: Cancer Journal - January 1, 2019 Category: Cancer & Oncology Authors: Nooka AK, Lonial S Tags: Cancer J Source Type: research

Are 4-Drug Regimens Here to Stay? Role in Induction and Salvage Therapies.
Abstract With 10 novel therapies approved across the decade, the multiple myeloma (MM) treatment paradigm continues to evolve in breadth and complexity. The current gestalt of the day has been the emergence of data to support 3-drug combinations over their 2-drug counterparts. Current guidelines and consensus statements support this approach. With the recent incorporation of monoclonal antibodies into the fray of myeloma therapy, we have begun to ask what the roles of 4-drug combinations are in both the upfront and the relapsed and refractory settings. The recent approval of daratumumab in combination with bortezo...
Source: Cancer Journal - January 1, 2019 Category: Cancer & Oncology Authors: Richter J, Jagannath S Tags: Cancer J Source Type: research

Cellular Immunotherapy for Multiple Myeloma.
Abstract Cellular immunotherapy for myeloma has the unique potential both to potently kill the malignant clone and to evoke a memory response to protect from relapse. Understanding the complex interactions between the malignant clone and the microenvironment that promote immune escape is critical to evoke effective antimyeloma immunity. Tremendous progress has been made in the area of cancer vaccines and adoptive T-cell therapy in recent years. Careful study of the mechanisms of response and of immune escape will be critical to developing novel combination therapies and ultimately to improve outcomes for patients ...
Source: Cancer Journal - January 1, 2019 Category: Cancer & Oncology Authors: Rosenblatt J, Avigan D Tags: Cancer J Source Type: research

Novel Agents in Multiple Myeloma.
Abstract The therapeutic landscape of multiple myeloma (MM) has dramatically changed in the last 15 years with the advent of immunomodulatory drugs and proteasome inhibitors. However, majority of MM patients relapse, and new therapies are needed. Various agents with diverse mechanisms of action and distinct targets, including cellular therapies, monoclonal antibodies, and small molecules, are currently under investigation. In this review, we report novel drugs recently approved or under advanced investigation that will likely be incorporated in the future as new standard for MM treatment, focusing on their mechani...
Source: Cancer Journal - January 1, 2019 Category: Cancer & Oncology Authors: Szalat R, Munshi NC Tags: Cancer J Source Type: research

Risk-Based Therapeutic Strategies.
Abstract Although therapeutic strategies have been adapted to age and comorbidities of myeloma patients for a long time, all patients currently experiment the same treatment whatever their genomic risk. However, high-risk patients should benefit right now from the most efficient drugs combinations. Herein, we review and discuss how to optimally define risk to adapt treatment and why a modern multiparametric definition of genomic risk is urgently needed. Minimal residual disease status will probably also take a growing place in patient's management, including in treatment adaptation. We also discuss how next-genera...
Source: Cancer Journal - January 1, 2019 Category: Cancer & Oncology Authors: Corre J, Avet-Loiseau H Tags: Cancer J Source Type: research

Targeted Management Strategies in Multiple Myeloma.
Abstract There has been a paradigm shift in the treatment of myeloma triggered by intense exploration of the disease biology to understand the basis of disease development and progression and the evolution of newly diagnosed myeloma to a multidrug refractory state that is associated with poor survival. These studies have in turn informed us of potential therapeutic strategies in our ongoing effort to cure this disease, or at a minimum convert it into a chronic disease. Given the clonal evolution that leads to development of drug resistance and treatment failure, identification of specific genetic abnormalities and...
Source: Cancer Journal - January 1, 2019 Category: Cancer & Oncology Authors: Kumar SK Tags: Cancer J Source Type: research

Smoldering Multiple Myeloma: To Treat or Not to Treat.
Abstract Smoldering multiple myeloma (SMM) is an asymptomatic, intermediate stage positioned between the plasma cell disorders of monoclonal gammopathy of undermined significance and overt multiple myeloma (MM). Although the patients with SMM have a higher risk of progression to MM in comparison to their counterparts with monoclonal gammopathy of undermined significance, their clinical course can be highly variable. The standard of care for SMM, irrespective of the risk status, continues to be observation due to paucity of high-level evidence demonstrating survival or quality-of-life benefit with early interventio...
Source: Cancer Journal - January 1, 2019 Category: Cancer & Oncology Authors: Kapoor P, Rajkumar SV Tags: Cancer J Source Type: research

Introduction by the Guest Editor: Ronald Barr.
Authors: PMID: 30480569 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - November 1, 2018 Category: Cancer & Oncology Tags: Cancer J Source Type: research

Cancer Burden in Adolescents and Young Adults: A Review of Epidemiological Evidence.
Abstract Cancer burden in adolescents and young adults (AYAs) is expressed through a large proportion of the quality of life lost on individual level and also causes losses to the society in terms of a decreased productivity and social structure. A specific cancer spectrum and distinctive needs of AYA patients require targeted studies and cancer control measures. Incidence is intermediate between that for children and for older adults, and two-thirds of the AYA cancers affect women. Cancers of the breast and cervix uteri, representing a large portion of the burden, are amenable to prevention. Survival is relativel...
Source: Cancer Journal - November 1, 2018 Category: Cancer & Oncology Authors: Trama A, Botta L, Steliarova-Foucher E Tags: Cancer J Source Type: research

Adolescent and Young Adult Cancer Biology.
Abstract Adolescent and young adult (AYA) patients with cancer have not attained the same improvements in overall survival as either younger children or older adults. One possible reason for this disparity may be that the AYA cancers exhibit unique biologic characteristics, resulting in differences in clinical and treatment resistance behaviors. Our current understanding of the unique biological/genomic characteristics of AYA cancers is limited. However, there has been some progress that has provided clues about the biology of AYA cancers. We here review the latest findings in the area of AYA cancer biology and di...
Source: Cancer Journal - November 1, 2018 Category: Cancer & Oncology Authors: Tricoli JV, Bleyer A Tags: Cancer J Source Type: research

Modifiable Risk Factors for the Development of Breast Cancer in Young Women.
CONCLUSIONS: Further research, ideally in large prospective trials, is needed to truly understand modifiable risk factors for the development of AYA breast cancer. PMID: 30480572 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - November 1, 2018 Category: Cancer & Oncology Authors: Cathcart-Rake EJ, Ruddy KJ, Johnson RH Tags: Cancer J Source Type: research

Lymphoma in Adolescents and Young Adults: Current Perspectives.
Abstract Lymphomas in adolescents and young adults represent approximately one quarter of all cancers in this age group. Historically, adolescent and young adult cancer patients represent a unique population with diverging issues surrounding psychosocial hardships/barriers, economics, and lack of standardization of therapeutic approaches.Furthermore, the biologic differences within the adolescent and young adult population seen in various lymphoma subtypes likely play a role in overall outcomes for this group. Without an organized approach to clinical and translational research for adolescent and young adult patie...
Source: Cancer Journal - November 1, 2018 Category: Cancer & Oncology Authors: Hochberg J, Cairo MS Tags: Cancer J Source Type: research

Challenges of Clinical Management of Adolescent and Young Adults With Bone and Soft Tissue Sarcoma.
Abstract Clinical management of adolescents and young adults with bone and soft tissue sarcomas is quite challenging, mainly because of different chemotherapy approaches adopted by pediatric and adult oncologists and tumor-associated factors related to this peculiar age group. Overcoming these barriers is essential for adolescent and young adult patients, whose survival and long-term physical effects are worse than their pediatric counterparts. Nowadays, constant efforts from international collaborations between pediatric and adult oncologists of sarcoma groups have optioned in converging toward a common therapeut...
Source: Cancer Journal - November 1, 2018 Category: Cancer & Oncology Authors: Ferrari A, Gasparini P, Gill J, Gorlick R Tags: Cancer J Source Type: research

Dynamics and Challenges of Clinical Trials in Adolescents and Young Adults With Cancer.
Abstract Inclusion in cancer clinical trials is considered the optimal standard of care, offering improved patient experience and progressive survival gains for subsequent generations of patients. Adolescent and young adult (AYA) patients are underrepresented in cancer research; consequently, improvements in outcomes for AYAs lag behind their pediatric and adult counterparts. Despite international evidence of underrepresentation in research, systematically tested interventions to improve recruitment for AYAs do not exist, and recruitment rates for AYAs continue to be lower than those for children. We review recrui...
Source: Cancer Journal - November 1, 2018 Category: Cancer & Oncology Authors: Fern LA, Bleyer A Tags: Cancer J Source Type: research

Models of Care-There Is More Than One Way to Deliver.
Abstract Adolescents and young adults (AYAs) with cancer constitute a particular group of patients with unique features, whose needs during and after treatment are poorly met. A standardized model of care for them has yet to be established, as neither the pediatric nor the adult oncology systems seamlessly fit their needs. Regardless of the setting in which they are treated, their health care providers should be aware of the impact that the disease and its treatments have on these especially vulnerable patients. Simple ways of improving the AYA experience should be considered: reducing isolation through connection...
Source: Cancer Journal - November 1, 2018 Category: Cancer & Oncology Authors: Sironi G, Barr RD, Ferrari A Tags: Cancer J Source Type: research

Psychosocial Support in Adolescents and Young Adults With Cancer.
This article focuses on psychosocial interventions for AYAs aged 15 to 39 years with cancer at diagnosis, during treatment, and shortly after. PMID: 30480577 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - November 1, 2018 Category: Cancer & Oncology Authors: Penn A, Kuperberg A Tags: Cancer J Source Type: research

Oncofertility: Meeting the Fertility Goals of Adolescents and Young Adults With Cancer.
Abstract Adolescents and young adults aged 15 to 39 years who are diagnosed with cancer (AYA survivors) undergo a range of therapies for cancer cure but subsequently may be at risk of treatment-related infertility, and for female AYA survivors, adverse pregnancy outcomes. Future fertility is important to AYA survivors. Meeting their fertility goals requires awareness of this importance, knowledge of cancer treatment-related fertility risks, appropriate fertility counseling on these risks, and access to fertility care. Epidemiologic and dissemination and implementation research are needed to estimate more precise r...
Source: Cancer Journal - November 1, 2018 Category: Cancer & Oncology Authors: Irene Su H, Lee YT, Barr R Tags: Cancer J Source Type: research

Palliative Care in Adolescents and Young Adults With Cancer-Why Do Adolescents Need Special Attention?
Abstract Meeting shortfalls in the provision of care to adolescents and young adults with cancer has focused largely on improving outcomes and psychosocial support. A significant percentage of adolescents and young adults with cancer will die of disease because of initial poor prognosis conditions or disease relapse. In adults, progress has been made in the concept of an integrated cancer/palliative care service. In pediatric oncology, the application of this philosophy of care has lagged behind somewhat. In the case of adolescents, particularly those with advanced cancer, the palliative care needs, in a broader s...
Source: Cancer Journal - November 1, 2018 Category: Cancer & Oncology Authors: Pinkerton R, Donovan L, Herbert A Tags: Cancer J Source Type: research

Introduction From the Guest Editor: Hodgkin Lymphoma: Integrating New Therapies to Improve Outcomes.
PMID: 30247254 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - September 1, 2018 Category: Cancer & Oncology Authors: Connors JM Tags: Cancer J Source Type: research

Novel Biomarker Approaches in Classic Hodgkin Lymphoma.
Abstract Classic Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Advances in the management of cHL have led to high cure rates exceeding 80%. Nevertheless, relapse or refractory disease in a subset of patients and treatment-related toxicity still represents unsolved clinical problems. The introduction of targeted treatments such as PD-1 blockade and the CD30 antibody drug conjugate, brentuximab vedotin, has broadened treatment options in cHL, emphasizing the critical need to identify biomarkers with the goal to provide rationales for treatment selection, increase effective drug uti...
Source: Cancer Journal - September 1, 2018 Category: Cancer & Oncology Authors: Aoki T, Steidl C Tags: Cancer J Source Type: research

Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography.
Abstract 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG PET/CT) is currently the criterion standard of lymphoma imaging and recommended through all stages of Hodgkin lymphoma management. Accurate staging is important for risk stratification and initial choice of therapy and also for the planning of postchemoradiotherapy. 18-Fluoro-2-deoxy-D-glucose PET/CT frequently leads to upstaging and potentially a more intensive treatment. Visual-only assessment of staging and interim scans is being accompanied by quantitative and semiquantitative methods to measure metabolic tumor volume, t...
Source: Cancer Journal - September 1, 2018 Category: Cancer & Oncology Authors: Hutchings M Tags: Cancer J Source Type: research

Limited-Stage Hodgkin Lymphoma: Minimizing Toxicity.
Abstract Early-stage classic Hodgkin lymphoma has been highly curable using extended-field radiation therapy (RT) alone, combined-modality therapy consisting of chemotherapy and RT, and more recently chemotherapy alone. Radiation therapy either to an extended field (extended-field RT) or to various iterations of an involved field (involved-field RT) is potentially associated with late morbidity and mortality, particularly second primary cancers and cardiovascular complications. Treatment with chemotherapy alone, when possible, can achieve a high cure rate while avoiding these risks. This review describes the evolu...
Source: Cancer Journal - September 1, 2018 Category: Cancer & Oncology Authors: Straus DJ Tags: Cancer J Source Type: research

Advanced-Stage Hodgkin Lymphoma: New Approaches Based on Novel Therapeutic Agents or Treatment Intensification.
This article discusses these exciting new developments in the treatment of advanced-stage Hodgkin lymphoma. PMID: 30247258 [PubMed - in process] (Source: Cancer Journal)
Source: Cancer Journal - September 1, 2018 Category: Cancer & Oncology Authors: Connors JM Tags: Cancer J Source Type: research